Impact of karyotype on treatment outcome in acute myeloid leukemia.

D. Grimwade, Anthony Moorman, R. Hills, K. Wheatley, H. Walker, G. Harrison, C. Harrison, A. Goldstone, A. Burnett

Research output: Contribution to journalReview article

Abstract

Over the course of the last three decades it has become apparent that the majority of cases of acute myeloid leukemia (AML) are characterized by at least one of a variety of recurrent chromosomal abnormalities. Whilst in many instances it remains uncertain as to which abnormalities represent primary events in the pathogenesis of AML, those which provide critical second hits that are required for progression to full blown leukemia or those that are merely markers of the leukemic process, it is nevertheless clear that diagnostic karyotype is a key determinant of outcome in this disease. Indeed there is mounting evidence to support the notion that cytogenetic analysis can serve to identify biologically distinct subsets of AML that demand tailored therapeutic approaches. This underpins the trend towards more widespread adoption of routine cytogenetic and molecular analysis in the characterization of patients with a diagnosis of acute leukemia. A key challenge for the future is to use this information to achieve greater consensus in risk group assignment of AML which will provide a more reliable framework for determining the most appropriate treatment approach for individual patients with this disease.

Original languageEnglish (US)
JournalAnnals of Hematology
Volume83 Suppl 1
StatePublished - Jul 2 2004
Externally publishedYes

Fingerprint

Karyotype
Acute Myeloid Leukemia
Cytogenetic Analysis
Leukemia
Chromosome Aberrations
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Grimwade, D., Moorman, A., Hills, R., Wheatley, K., Walker, H., Harrison, G., ... Burnett, A. (2004). Impact of karyotype on treatment outcome in acute myeloid leukemia. Annals of Hematology, 83 Suppl 1.

Impact of karyotype on treatment outcome in acute myeloid leukemia. / Grimwade, D.; Moorman, Anthony; Hills, R.; Wheatley, K.; Walker, H.; Harrison, G.; Harrison, C.; Goldstone, A.; Burnett, A.

In: Annals of Hematology, Vol. 83 Suppl 1, 02.07.2004.

Research output: Contribution to journalReview article

Grimwade, D, Moorman, A, Hills, R, Wheatley, K, Walker, H, Harrison, G, Harrison, C, Goldstone, A & Burnett, A 2004, 'Impact of karyotype on treatment outcome in acute myeloid leukemia.', Annals of Hematology, vol. 83 Suppl 1.
Grimwade D, Moorman A, Hills R, Wheatley K, Walker H, Harrison G et al. Impact of karyotype on treatment outcome in acute myeloid leukemia. Annals of Hematology. 2004 Jul 2;83 Suppl 1.
Grimwade, D. ; Moorman, Anthony ; Hills, R. ; Wheatley, K. ; Walker, H. ; Harrison, G. ; Harrison, C. ; Goldstone, A. ; Burnett, A. / Impact of karyotype on treatment outcome in acute myeloid leukemia. In: Annals of Hematology. 2004 ; Vol. 83 Suppl 1.
@article{52908b5519fb4ce781eb465698430726,
title = "Impact of karyotype on treatment outcome in acute myeloid leukemia.",
abstract = "Over the course of the last three decades it has become apparent that the majority of cases of acute myeloid leukemia (AML) are characterized by at least one of a variety of recurrent chromosomal abnormalities. Whilst in many instances it remains uncertain as to which abnormalities represent primary events in the pathogenesis of AML, those which provide critical second hits that are required for progression to full blown leukemia or those that are merely markers of the leukemic process, it is nevertheless clear that diagnostic karyotype is a key determinant of outcome in this disease. Indeed there is mounting evidence to support the notion that cytogenetic analysis can serve to identify biologically distinct subsets of AML that demand tailored therapeutic approaches. This underpins the trend towards more widespread adoption of routine cytogenetic and molecular analysis in the characterization of patients with a diagnosis of acute leukemia. A key challenge for the future is to use this information to achieve greater consensus in risk group assignment of AML which will provide a more reliable framework for determining the most appropriate treatment approach for individual patients with this disease.",
author = "D. Grimwade and Anthony Moorman and R. Hills and K. Wheatley and H. Walker and G. Harrison and C. Harrison and A. Goldstone and A. Burnett",
year = "2004",
month = "7",
day = "2",
language = "English (US)",
volume = "83 Suppl 1",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Impact of karyotype on treatment outcome in acute myeloid leukemia.

AU - Grimwade, D.

AU - Moorman, Anthony

AU - Hills, R.

AU - Wheatley, K.

AU - Walker, H.

AU - Harrison, G.

AU - Harrison, C.

AU - Goldstone, A.

AU - Burnett, A.

PY - 2004/7/2

Y1 - 2004/7/2

N2 - Over the course of the last three decades it has become apparent that the majority of cases of acute myeloid leukemia (AML) are characterized by at least one of a variety of recurrent chromosomal abnormalities. Whilst in many instances it remains uncertain as to which abnormalities represent primary events in the pathogenesis of AML, those which provide critical second hits that are required for progression to full blown leukemia or those that are merely markers of the leukemic process, it is nevertheless clear that diagnostic karyotype is a key determinant of outcome in this disease. Indeed there is mounting evidence to support the notion that cytogenetic analysis can serve to identify biologically distinct subsets of AML that demand tailored therapeutic approaches. This underpins the trend towards more widespread adoption of routine cytogenetic and molecular analysis in the characterization of patients with a diagnosis of acute leukemia. A key challenge for the future is to use this information to achieve greater consensus in risk group assignment of AML which will provide a more reliable framework for determining the most appropriate treatment approach for individual patients with this disease.

AB - Over the course of the last three decades it has become apparent that the majority of cases of acute myeloid leukemia (AML) are characterized by at least one of a variety of recurrent chromosomal abnormalities. Whilst in many instances it remains uncertain as to which abnormalities represent primary events in the pathogenesis of AML, those which provide critical second hits that are required for progression to full blown leukemia or those that are merely markers of the leukemic process, it is nevertheless clear that diagnostic karyotype is a key determinant of outcome in this disease. Indeed there is mounting evidence to support the notion that cytogenetic analysis can serve to identify biologically distinct subsets of AML that demand tailored therapeutic approaches. This underpins the trend towards more widespread adoption of routine cytogenetic and molecular analysis in the characterization of patients with a diagnosis of acute leukemia. A key challenge for the future is to use this information to achieve greater consensus in risk group assignment of AML which will provide a more reliable framework for determining the most appropriate treatment approach for individual patients with this disease.

UR - http://www.scopus.com/inward/record.url?scp=3042632349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042632349&partnerID=8YFLogxK

M3 - Review article

VL - 83 Suppl 1

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -